Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference

Michael B. Atkins, Ronald M. Bukowski, Bernard J. Escudier, Robert A. Figlin, Gary H. Hudes, William G. Kaelin, W. Marston Linehan, David F. McDermott, James W. Mier, Ivan Pedrosa, Brian I. Rini, Sabina Signoretti, Jeffrey A. Sosman, Bin Tean Teh, Christopher G. Wood, Amado J. Zurita, Laura King

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

The Third Cambridge Conference on Innovations and Challenges in Renal Cancer, a symposium held in Cambridge, Massachusetts, June 27-28, 2008, and chaired by Michael B. Atkins, was convened to discuss the current state of knowledge in the field, critique new data, stimulate communication among those involved in basic and clinical research, and offer recommendations for further study. Four main topics were discussed: genetics and molecular biology of renal cell cancer, staging and prognosis, systemic therapy, and correlative science and biomarkers in stage IV disease. The conference format combined brief presentations with extended periods of discussion. The conclusions and recommendations are summarized in this paper and presented in more detail in the individual papers that follow.

Original languageEnglish (US)
Pages (from-to)2247-2251
Number of pages5
JournalCancer
Volume115
Issue numberSUPPL. 10
DOIs
StatePublished - May 15 2009

    Fingerprint

Keywords

  • Biomarkers
  • Genetics
  • Immunotherapy
  • Renal cancer
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Atkins, M. B., Bukowski, R. M., Escudier, B. J., Figlin, R. A., Hudes, G. H., Kaelin, W. G., Linehan, W. M., McDermott, D. F., Mier, J. W., Pedrosa, I., Rini, B. I., Signoretti, S., Sosman, J. A., Teh, B. T., Wood, C. G., Zurita, A. J., & King, L. (2009). Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer, 115(SUPPL. 10), 2247-2251. https://doi.org/10.1002/cncr.24229